Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children
Public ClinicalTrials.gov record NCT03826901. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1 Open-label, Multi-centre, Single-arm Trial to Evaluate the Safety and Pharmacokinetics (Including MUsT) of Twice Daily Topical Application of Delgocitinib Cream for 8 Weeks in Adults, Adolescents, and Children With Moderate to Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multi-center, open-label trial to evaluate safety and pharmacokinetics of topical delgocitinib cream applied to pediatric subjects (2-17 years) and adult subjects (18 years and above) with atopic dermatitis.
Study identification
- NCT ID
- NCT03826901
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 46 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 2 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 19, 2019
- Primary completion
- Oct 28, 2021
- Completion
- Oct 28, 2021
- Last update posted
- Feb 23, 2025
2019 – 2021
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| LEO Pharma investigational site | Birmingham | Alabama | 35209 | — |
| LEO Pharma investigational site | Phoenix | Arizona | 85006 | — |
| LEO Pharma investigational site | Fountain Valley | California | 92708 | — |
| LEO Pharma investigational site | Irvine | California | 92697 | — |
| LEO Pharma investigational site | Los Angeles | California | 90027 | — |
| LEO Pharma investigational site | Centennial | Colorado | 80112 | — |
| LEO Pharma investigational site | New Haven | Connecticut | 06519 | — |
| LEO Pharma investigational site | Indianapolis | Indiana | 46250 | — |
| LEO Pharma investigational site | Ypsilanti | Michigan | 48197 | — |
| LEO Pharma investigational site | Tulsa | Oklahoma | 74136 | — |
| LEO Pharma investigational site | Medford | Oregon | 97504 | — |
| LEO Pharma investigational site | San Antonio | Texas | 78218 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03826901, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 23, 2025 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03826901 live on ClinicalTrials.gov.